Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies
Said Moshawih, Qais Jarrar, Abdul Alim Bahrin, Ai Fern Lim, Long Ming, Hui Poh Goh
Heliyon, doi:10.1016/j.heliyon.2024.e25734
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely recognized for their analgesic and anti-inflammatory properties. Amidst the SARS-CoV-2 pandemic, the role of NSAIDs in modulating viral and bacterial infections has become a critical area of research, sparking debates and necessitating a thorough review. This review examines the multifaceted interactions between NSAIDs, immune responses, and infections. Focusing on the immunomodulatory mechanisms of NSAIDs in SARS-CoV-2 and their implications for other viral and bacterial infections, we aim to provide clarity and direction for future therapeutic strategies. NSAIDs demonstrate a dual role in infectious diseases. They reduce inflammation by decreasing neutrophil recruitment and cytokine release, yet potentially compromise antiviral defense mechanisms. They also modulate cytokine storms in SARS-CoV-2 and exhibit the potential to enhance anti-tumor immunity by inhibiting tumor-induced COX-2/PGE2 signaling. Specific NSAIDs have shown efficacy in inhibiting viral replication. The review highlights NSAIDs' synergy with other medications, like COX inhibitors and immunotherapy agents, in augmenting therapeutic effects. Notably, the World Health Organization's analysis found no substantial link between NSAIDs and the worsening of viral respiratory infections. The findings underscore NSAIDs' complex role in infection management. Understanding these interactions is crucial for optimizing therapeutic approaches in current and future pandemics. However, their dual nature warrants cautious application, particularly in vulnerable populations. NSAIDs present a paradoxical impact on immune responses in viral and bacterial infections. While offering potential benefits, their usage in infectious diseases, especially SARS-CoV-2, demands a nuanced understanding to balance therapeutic advantages against possible adverse effects.
Ethics approval and consent to participate Not applicable.
Consent for publication Not applicable.
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
-O. Zemlin, Wiese, Coronavirus Disease 2019 (COVID-19) and the Renin-Angiotensin System: A Closer Look at Angiotensin-Converting Enzyme, ACE
Abu Esba, Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study, Infect. Dis. Ther
Abu-Farha, The role of lipid metabolism in COVID-19 virus infection and as a drug target, Int. J. Mol. Sci
Al-Horani, Kar, Potential anti-SARS-CoV-2 therapeutics that target the post-entry stages of the viral life cycle: a comprehensive review, Viruses
Alberca, Obesity as a risk factor for COVID-19: an overview, Crit. Rev. Food Sci. Nutr
Albornoz, SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein, Mol. Psychiatr
Alfajaro, Activation of COX-2/PGE2 Promotes Sapovirus Replication via the Inhibition of Nitric Oxide Production,
doi:LID-10.1128/JVI.01656-16Alghamri, Enhanced Angiotensin II-Induced Cardiac and Aortic Remodeling in ACE2 Knockout Mice
Allen, Hallmarks of metabolic reprogramming and their role in viral pathogenesis, Viruses
Bancos, Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells, Cell. Immunol
Barletta, Risk factors of SARS-CoV-2 infection: global epidemiological study, JMIRx Med
Bruce, Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19, J. Clin. Med
Capuano, NSAIDs in patients with viral infections, including Covid-19: victims or perpetrators?, Pharmacol. Res
Carey, Contrasting Effects of Cyclooxygenase-1 (COX-1) and COX-2 Deficiency on the Host Response to Influenza A Viral Infection
Carey, Contrasting Effects of Cyclooxygenase-1 (COX-1) and COX-2 Deficiency on the Host Response to Influenza A Viral Infection
Chen, Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection, J. Virol
Chen, The NLRP3 inflammasome: an emerging therapeutic target for chronic pain, J. Neuroinflammation
Chen, Warner, Fau -Reiss, Reiss, NSAID Treatment Suppresses VSV Propagation in Mouse CNS
Ciaglia, Vecchione, Puca, COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children
Cianferoni, Selective inhibition of interleukin-4 gene expression in human T cells by aspirin, Blood
Cioccarelli, IL1β promotes TMPRSS2 expression and SARS-CoV-2 cell entry through the p38 MAPK-GATA2 Axis, Front. Immunol
Classen, Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO), Ann. Hematol
Collins, Belkaid, Control of immunity via nutritional interventions, Immunity
Coto, Avanzas, Gómez, The Renin-Angiotensin-Aldosterone System and Coronavirus Disease
Daniels, The nucleotide sensor ZBP1 and kinase RIPK3 induce the enzyme IRG1 to promote an antiviral metabolic state in neurons, Immunity
Douglas, The Novel Angiotensin-Converting Enzyme (ACE) Homolog, ACE2, Is Selectively Expressed by Adult Leydig Cells of the Testis
Drake, Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study, The Lancet Rheumatology
Faist, Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier, Antivir. Res
Fontaine, Dengue virus induces and requires glycolysis for optimal replication, J. Virol
Fukunaga, Cyclooxygenase 2 Plays a Pivotal Role in the Resolution of Acute Lung Injury
Gangitano, Ketogenic diet as a preventive and supportive care for COVID-19 patients, Nutrients
Gerges, NSAIDs: a double edged sword in viral infections, International Journal of Medical Reviews
Glowacka, Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response, J. Virol
Goel, SARS-CoV-2 switches 'on' MAPK and NFκB signaling via the reduction of nuclear DUSP1 and DUSP5 expression, Front. Pharmacol
Grimes, Grimes, p38 MAPK inhibition: a promising therapeutic approach for COVID-19, J. Mol. Cell. Cardiol
Gupta, The lactate and the lactate dehydrogenase in inflammatory diseases and major risk factors in COVID-19 patients, Inflammation
Hafeez, A review of COVID-19 (Coronavirus Disease-2019) diagnosis, treatments and prevention, Ejmo
Hafner-Bratkovic, Pelegrin, Ion homeostasis and ion channels in NLRP3 inflammasome activation and regulation, Curr. Opin. Immunol
Hamidi, Kadamboor, Veethil, Hamidi, Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective
Harris, COX-2 and the kidney, J. Cardiovasc. Pharmacol
Hoffmann, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Huang, CD8+ T cell exhaustion in anti-tumour immunity: the new insights for cancer immunotherapy, Immunology
Hunter, Wood, Dargan, The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open access emergency medicine, OAEM
Hussain, Non-steroidal Anti-inflammatory Drugs, Tumour Immunity and Immunotherapy
Ivashkiv, Donlin, Regulation of type I interferon responses, Nat. Rev. Immunol
Jin, Inhibition of Highly Pathogenic Avian H5N1 Influenza Virus Propagation by RNA Oligonucleotides Targeting the PB2 Gene in Combination with Celecoxib
Kaewput, Disorn, Satirapoj, Selective cyclooxygenase-2 inhibitor use and progression of renal function in patients with chronic kidney disease: a single-center retrospective cohort study, Int. J. Nephrol. Renovascular Dis
Kang, Tang, HIV-1 infection and glucose metabolism reprogramming of T cells: another approach toward functional cure and reservoir eradication, Front. Immunol
Kelleni, NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects, Expert Rev. Anti-infect. Ther
Khirfan, Analgesics induce alterations in the expression of SARS-CoV-2 entry and arachidonic-acid-metabolizing genes in the mouse lungs, Pharmaceuticals
Kiani, In vitro assessment of the antiviral activity of ketotifen, indomethacin and naproxen, alone and in combination, against SARS-CoV-2, Viruses
Kindler, Thiel, Weber, Interaction of SARS and MERS coronaviruses with the antiviral interferon response, Adv. Virus Res
Kirkby, Cyclooxygenase-2 selectively controls renal blood flow through a novel PPARβ/δ-dependent vasodilator pathway, Hypertension
Kragholm, Association between prescribed ibuprofen and severe COVID-19 infection: a nationwide register-based cohort study, Clinical and Translational Science
Kushner, The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19, NPJ Prim Care Respir Med
Lagadinou, Antimicrobial properties on non-antibiotic drugs in the era of increased bacterial resistance, Antibiotics
Lai, Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: perspectives in pharmacogenomics, Front. Pharmacol
Langhendries, Possible Effects of Repeated Exposure to Ibuprofen and Acetaminophen on the Intestinal Immune Response in Young Infants
Lau, Neutralizing antibody titres in SARS-CoV-2 infections, Nat. Commun
Legras, A multicentre case-control study of nonsteroidal anti-inflammatory drugs as a risk factor for severe sepsis and septic shock, Crit. Care
Lejal, Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus, Antimicrob. Agents Chemother
Li, Angiotensin-converting Enzyme 2 Is a Functional Receptor for the SARS Coronavirus
Liu, Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways, Faseb. J
Lucas, Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature
Lund, Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study, PLoS Med
Man, Ibuprofen-associated hypokalemia and metabolic acidosis: systematic literature review, Ann. Pharmacother
Matsuyama, Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, Proc. Natl. Acad. Sci. USA
Mayer, Hijacking the supplies: metabolism as a novel facet of virus-host interaction, Front. Immunol
Meinberger, Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19, Sci. Rep
Micallef, Soeiro, Jonville-Béra, Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection, Therapies
Moshawih, None, Heliyon
Nainu, Mamada, Emran, Prospective role of NSAIDs with antiviral properties for pharmacological management of postsurgical procedures during COVID-19, Int. J. Surg
Nilsson-Payant, The NF-κB transcriptional footprint is essential for SARS-CoV-2 replication, J. Virol
Ocaña, Nonsteroidal anti-inflammatory drugs sensitize epithelial cells to Clostridioides difficile toxin-mediated mitochondrial damage, Sci. Adv
Oh, Adnan, Cho, Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19, Sci. Rep
Organization, Scientific Brief: the Use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Patients with COVID-19
Peng, Structural and Biochemical Characterization of Nsp12-Nsp7-Nsp8 Core Polymerase Complex from COVID-19 Virus
Pommier, NSAIDs for Pain Control during the Peri-Operative Period of Hip Fracture Surgery: A Systematic Review, Drugs & Aging
Powis, NHS MEDICAL DIRECTOR Novel Coronavirus Anti-inflammatory Medications
Prasher, Sharma, Gunupuru, Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy, Drug Dev. Res
Pu, Cyclooxygenase-2 inhibitor: a potential combination strategy with immunotherapy in cancer, Front. Oncol
Reese, NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study, Virol. J
Rohaim, Structural and functional insights into non-structural proteins of coronaviruses, Microb. Pathog
Sartorius, Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines, npj Vaccines
Serhan, Pro-resolving lipid mediators are leads for resolution physiology, Nature
Shagufta, Ahmad, The Race to Treat COVID-19: Potential Therapeutic Agents for the Prevention and Treatment of SARS-CoV-2
Shaheed, Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: mechanisms and relevance to infection, Br. J. Clin. Pharmacol
Sharif-Askari, Effect of Common Medications on the Expression of SARS-CoV-2 Entry Receptors in Kidney Tissue
Sheridan, Obesity is associated with impaired immune response to influenza vaccination in humans, Int. J. Obes
Shimizu, Impact of COX2 inhibitor for regulation of PD-L1 expression in non-small cell lung cancer, Anticancer Res
Sireesh, Association of NF-E2 related factor 2 (Nrf2) and inflammatory cytokines in recent onset type 2 diabetes mellitus, Sci. Rep
Sisakht, Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: non-steroidal anti-inflammatory drugs against COVID-19, Comput. Biol. Med
Smythe, NSAIDs inhibit p38 MAPK activation, Arthritis Res. Ther
Stuve, Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populations, Ther Adv Neurol Disord
Sumbria, Virus infections and host metabolism-can we manage the interactions?, Front. Immunol
Talty, Ibuprofen induces ferroptosis to potentiate antitumor immunity, Cancer Res
Tang, Current status and future directions of bacteria-based immunotherapy, Front. Immunol
Tang, Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors, Nat. Rev. Drug Discov
Terrier, Antiviral properties of the NSAID drug naproxen targeting the nucleoprotein of SARS-CoV-2 coronavirus, Molecules
Thabet, A Double Edged Sword in Viral Infections
Tomera, Joseph kittah, Hospitalized COVID-19 Patients Treated with Celecoxib and High Dose Famotidine Adjuvant Therapy Show Significant Clinical Responses
Turnier, Bacterial infections and NSAIDs exposure? Seek septic complications, Eur. J. Intern. Med
Valipour, Therapeutic prospects of naturally occurring p38 MAPK inhibitors tanshinone IIA and pinocembrin for the treatment of SARS-CoV-2-induced CNS complications, Phytother Res
Vastag, Divergent effects of human cytomegalovirus and herpes simplex virus-1 on cellular metabolism, PLoS Pathog
Voilley, Nonsteroid Anti-inflammatory Drugs Inhibit Both the Activity and the Inflammation-Induced Expression of Acid-Sensing Ion Channels in Nociceptors
Voiriot, Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients, J. Clin. Med
Wallis, Host-directed immunotherapy of viral and bacterial infections: past, present and future, Nat. Rev. Immunol
Wang, Yang, Zhao, Co-crystallization and structure determination: an effective direction for anti-SARS-CoV-2 drug discovery, Comput. Struct. Biotechnol. J
Who, The Use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Patients with COVID-19
Yan, Guo, Zhu, Effects of Nonsteroidal Anti-inflammatory Drugs on Serum Proinflammatory Cytokines in the Treatment of Ankylosing Spondylitis
Yan, Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factorkappa B and CCAAT/enhancer binding protein, Int. J. Biochem. Cell Biol
Yi, Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives, Front. Oncol
Zhang, Angiotensin-converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target
Zhuang, Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection, J. Med. Virol
Zou, Single-cell RNA-Seq Data Analysis on the Receptor ACE2 Expression Reveals the Potential Risk of Different Human Organs Vulnerable to 2019-nCoV Infection
